Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 3Urinary Bladder Neoplasms 2Urethral Neoplasms 1Ureteral Neoplasms 1Neoplasm Metastasis 1Kidney Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

aldesleukin 43Sunitinib 42Cyclophosphamide 30Nivolumab 29pembrolizumab 27Everolimus 27Interferon-alpha 25Bevacizumab 23Sorafenib 22Interleukin-2 20fludarabine phosphate 19Radiotherapy 18Ipilimumab 18Filgrastim 18Axitinib 18Gene Expression Profiling 16Peripheral Blood Stem Cell Transplantation 15Gemcitabine 15cabozantinib 14Radiosurgery 13fludarabine 11Doxorubicin 11Carboplatin 11Blood Specimen Collection 11temsirolimus 10atezolizumab 9Immunohistochemistry 9Etoposide 9Chemotherapy, Adjuvant 9sargramostim 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × Propranolol × Genitourinary × Clear all
NCT03323710 2019-01-09

Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma

Military Institute od Medicine National Research Institute

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡